6FS2

MCL1 in complex with indole acid ligand

Summary for 6FS2

• Entry DOI: 10.2210/pdb6fs2/pdb
• Descriptor: Induced myeloid leukemia cell differentiation protein Mcl-1, 7-(2-methylphenyl)-3-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propyl]-1~{H}-indole-2-carboxylic acid (3 entities in total)
• Functional Keywords: mcl1, indole acid, immune system
• Biological source: Homo sapiens (Human)
• Total number of polymer chains: 2
• Total formula weight: 36932.07

Authors

Hargreaves, D. (deposition date: 2018-02-18, release date: 2018-12-26, Last modification date: 2024-05-08)

Primary citation

Tron, A.E.,Belmonte, M.A.,Adam, A.,Aquila, B.M.,Boise, L.H.,Chiarparin, E.,Cidado, J.,Embrey, K.J.,Gangl, E.,Gibbons, F.D.,Gregory, G.P.,Hargreaves, D.,Hendricks, J.A.,Johannes, J.W.,Johnstone, R.W.,Kazmirski, S.L.,Kettle, J.G.,Lamb, M.L.,Matulis, S.M.,Nooka, A.K.,Packer, M.J.,Peng, B.,Rawlins, P.B.,Robbins, D.W.,Schuller, A.G.,Su, N.,Yang, W.,Ye, Q.,Zheng, X.,Secrist, J.P.,Clark, E.A.,Wilson, D.M.,Fawell, S.E.,Hird, A.W.
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Nat Commun, 9:5341-5341, 2018

PubMed Abstract: Mcl-1 is a member of the Bcl-2 family of proteins that promotes cell survival by preventing induction of apoptosis in many cancers. High expression of Mcl-1 causes tumorigenesis and resistance to anticancer therapies highlighting the potential of Mcl-1 inhibitors as anticancer drugs. Here, we describe AZD5991, a rationally designed macrocyclic molecule with high selectivity and affinity for Mcl-1 currently in clinical development. Our studies demonstrate that AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway. AZD5991 shows potent antitumor activity in vivo with complete tumor regression in several models of multiple myeloma and acute myeloid leukemia after a single tolerated dose as monotherapy or in combination with bortezomib or venetoclax. Based on these promising data, a Phase I clinical trial has been launched for evaluation of AZD5991 in patients with hematological malignancies (NCT03218683).

PubMed: 30559424
DOI: 10.1038/s41467-018-07551-w

Experimental method

X-RAY DIFFRACTION (2.55 Å)